{
    "clinical_study": {
        "@rank": "156504", 
        "arm_group": {
            "arm_group_label": "Ramelteon 8 mg administered orally once daily"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety and efficacy of ramelteon (Rozerem)\n      when used in the routine clinical setting in patients with sleep-onset difficulty associated\n      with insomnia."
        }, 
        "brief_title": "Ramelteon Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With Sleep-onset Difficulty", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Insomnia", 
        "condition_browse": {
            "mesh_term": "Sleep Initiation and Maintenance Disorders"
        }, 
        "detailed_description": {
            "textblock": "This is a drug use surveillance planned to examine the safety and efficacy of ramelteon\n      tablets when used in the routine clinical setting in patients with sleep-onset difficulty\n      associated with insomnia (planned sample size, 3000)\n\n      The usual adult dosage is 8 mg of ramelteon administered orally once daily at bedtime."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1. Sleep-onset difficulty associated with insomnia\n\n        Exclusion Criteria:\n\n          1. Patients with previous history of hypersensitivity to an ingredient of Rozerem\n             Tablets\n\n          2. Patients with severe liver dysfunction\n\n          3. Patients taking fluvoxamine maleate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Insomnia"
            }
        }, 
        "enrollment": {
            "#text": "3339", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02058992", 
            "org_study_id": "293-101", 
            "secondary_id": "JapicCTI-132358"
        }, 
        "intervention": {
            "arm_group_label": "Ramelteon 8 mg administered orally once daily", 
            "description": "Ramelteon 8 mg tablets", 
            "intervention_name": "Ramelteon", 
            "intervention_type": "Drug", 
            "other_name": "Rozerem"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Drug therapy", 
        "lastchanged_date": "February 7, 2014", 
        "number_of_groups": "1", 
        "official_title": "Rozerem Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With Sleep-onset Difficulty", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The frequency of adverse drug reactions by type, seriousness, time to onset. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. Among these, events which are considered possibly associated with the study drug are defined as adverse drug reactions.", 
            "measure": "Frequency of adverse drug reactions", 
            "safety_issue": "Yes", 
            "time_frame": "From baseline to Week 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02058992"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The change in sleep status (sleep onset latency, total sleep time, number of awakenings) from the start of the investigation will be summarized and assessed.", 
                "measure": "Sleep status (sleep onset latency, total sleep time, number of awakenings)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 4 weeks of treatment"
            }, 
            {
                "description": "The results of the survey using the PGI questionnaire will be scored, and 7 items (sleep onset, sleep time, sleep quality, morning awakening, morning tiredness, daytime somnolence, and daytime physical condition/function) will be summarized and assessed.", 
                "measure": "The patient's score on the Global Impression (PGI) scale", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 4 weeks of treatment"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}